MYGN
MYRIAD GENETICS INC
+0.13 (+3.24%)3.99USD1.1M成交股數381M市值–本益比(近四季)0.5股價營收比-10.5%營收年增(近四季)2026-11-02下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 191M-3% | 200M-5% | 206M-4% | 213M+1% | 196M-3% | 211M+10% | 213M+16% | 212M+17% | 202M | 192M | 184M | 181M |
| 營業成本 | 63.7M | 62.8M | 61.9M | 61.3M | 61.7M | 59.7M | 63.5M | 64.4M | 64.6M | 57.6M | 57.8M | 59.2M |
| 毛利 | 127M-5% | 138M-9% | 144M-4% | 152M+3% | 134M-2% | 151M+12% | 150M+19% | 147M+21% | 138M | 134M | 126M | 122M |
| 毛利率 | 66.6% | 68.7% | 69.9% | 71.2% | 68.5% | 71.7% | 70.2% | 69.6% | 68.1% | 70.0% | 68.5% | 67.3% |
| 研發費用 | 25.0M | 27.1M | 28.2M | 25.6M | 27.5M | 32.9M | 28.5M | 27.1M | 24.9M | 24.0M | 21.2M | 22.5M |
| 銷售管理費用 | 57.8M | 62.2M | 67.9M | 66.8M | 66.5M | −149M | 139M | 145M | 141M | 136M | 141M | 152M |
| 營業利益 | −38.9M+34% | −30.7M-21% | −23.3M+17% | −329M+802% | −29.0M+4% | −39.1M-35% | −20.0M-82% | −36.5M-30% | −27.9M | −60.1M | −114M | −52.2M |
| 營業利益率 | -20.4% | -15.3% | -11.3% | -154.5% | -14.8% | -18.6% | -9.4% | -17.3% | -13.8% | -31.3% | -62.0% | -28.8% |
| 稅後淨利 | −43.2M+43100% | −34.1M-19% | −27.4M+24% | −331M+801% | −100K-100% | −42.2M-31% | −22.1M-81% | −36.7M-33% | −26.0M | −61.3M | −116M | −54.7M |
| 淨利率 | -22.7% | -17.0% | -13.3% | -155.1% | -0.1% | -20.0% | -10.4% | -17.4% | -12.9% | -31.9% | -63.3% | -30.2% |
| 稀釋 EPS | -0.46 | -0.36-23% | -0.29+21% | -3.57+771% | 0.00-100% | -0.47-37% | -0.24-83% | -0.41-39% | -0.29 | -0.75 | -1.42 | -0.67 |
| 稀釋股數 | 94.8M | 93.7M | 93.1M | 92.5M | 91.4M | 90.6M | 90.9M | 90.6M | 89.9M | 81.9M | 81.7M | 81.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 115M | 124M | 145M | 74.4M | 91.8M | 102M | 99.9M | 92.4M | 96.9M | 76.0M | 103M | 53.6M |
| 應收帳款 | 110M | 124M | 118M | 137M | 120M | 121M | 126M | 118M | 118M | 115M | 112M | 119M |
| 存貨 | 30.6M | 27.9M | 31.6M | 28.7M | 28.3M | 27.5M | 26.2M | 26.1M | 24.6M | 25.1M | 22.5M | 21.8M |
| 總資產 | 639M | 674M | 728M | 677M | 1.0B | 1.0B | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B |
| 有息負債 | 121M | 120M | 120M | 0.00 | 59.3M | 39.6M | 39.0M | 38.8M | 38.7M | 38.5M | 38.4M | 0.00 |
| 總負債 | 335M | 336M | 355M | 289M | 301M | 327M | 350M | 345M | 351M | 466M | 452M | 334M |
| 股東權益 | 304M | 337M | 373M | 388M | 705M | 701M | 732M | 741M | 760M | 683M | 735M | 835M |
| 負債比 | 52.4% | 49.9% | 48.8% | 42.7% | 29.9% | 31.8% | 32.3% | 31.8% | 31.6% | 40.5% | 38.1% | 28.6% |
| 淨現金(現金 − 有息負債) | −5.5M | 4.1M | 25.9M | 74.4M | 32.5M | 62.8M | 60.9M | 53.6M | 58.2M | 37.5M | 64.4M | 53.6M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −15.7M | – | – | −16.3M-12% | – | – | – | −18.6M | – | – | −33.2M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | 23.5M |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | −56.7M |
| 折舊攤銷 | – | 12.5M | – | – | 14.4M | – | – | – | 15.7M | – | – | 19.4M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | -31.3% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 825M
| 美國 | 768M | 93.1% | -0.2% |
|---|---|---|---|
| 美國以外 | 56.5M | 6.9% | -17.0% |
產品／服務2025 年度 · 825M
| Hereditary Cancer | 372M | 45.2% | +2.2% |
|---|---|---|---|
| Prenatal | 186M | 22.6% | +5.2% |
| Mental Health | 144M | 17.5% | -15.3% |
| Tumor Profiling | 122M | 14.8% | -3.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 825M | -1.6% | −366M | -44.4% | -3.95 | – |
| FY2024 | 838M | +11.2% | −127M | -15.2% | -1.41 | – |
| FY2023 | 753M | +11.0% | −263M | -34.9% | -3.18 | – |
| FY2022 | 678M | -1.8% | −112M | -16.5% | -1.39 | −152M |
| FY2021 | 691M | +24.0% | −27.0M | -3.9% | -0.35 | 600K |
| FY2020 | 557M | -12.8% | −224M | -40.1% | -2.99 | – |
| FY2020 | 639M | -25.0% | −200M | -31.2% | -2.69 | 50.5M |
| FY2019 | 851M | – | 4.6M | 0.5% | 0.06 | 75.1M |